Status:
UNKNOWN
IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment
Lead Sponsor:
University of Padova
Collaborating Sponsors:
Associazione Italiana per la Ricerca sul Cancro
Istituto Oncologico Veneto IRCCS
Conditions:
Rectal Cancer Stage T1-T2
Rectal Cancer Nodal Metastasis
Eligibility:
All Genders
18+ years
Brief Summary
ABSTRACT Background The current management on rectal cancer based on TNM staging has some limitations. In early rectal cancer T stage can be not sufficient to predict the nodal status and, in locally ...
Detailed Description
Background The introduction of new technologies for diagnosis and screening programs led to an increasing rate of early detection of colorectal cancer \[9\]. This, combined to the evolution of techniq...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 1\. T1 and T2 rectal carcinoma operated on will be included in the study group. 2. A minimal number of 10 retrieved lymph nodes will be required for the inclusion in case of anterior resection or Miles abdominal perineal resection 3. Full availability of clinical records and at least 1 year of follow up
- \-
Exclusion
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
466 Patients enrolled
Trial Details
Trial ID
NCT04915326
Start Date
January 1 2020
End Date
December 31 2024
Last Update
June 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedale Università di Padova
Padua, Italy, 35128